Associated factors | Positive SARS- CoV- 2 (n = 641 [%]) | Unadjusted | Adjusted | |||||
---|---|---|---|---|---|---|---|---|
Beta (95% CI) | p-value | Beta (95% CI) | p-value | |||||
Gender | ||||||||
Male | 351 (69.8) | Reference | Reference | |||||
Female | 290 (67.0) | 1.36 (-0.53–3.25) | 0.158 | 1.19 (-0.74–3.12) | 0.227 | |||
Age (years) | ||||||||
3–6 | 108 (58.4) | Reference | Reference | |||||
7–9 | 175 (73.8) | 0.09 (-2.81–2.99) | 0.952 | -0.36 (-3.53–2.80) | 0.821 | |||
10–12 | 213 (72.0) | 2.87 (0.08–5.67) | 0.044* | 2.94 (-0.16–6.04) | 0.064 | |||
13–16 | 145 (66.5) | 3.37 (0.36–6.38) | 0.028* | 3.60 (0.32–6.88) | 0.032* | |||
Time between last vaccination and COVID-19 infection (n = 574)#) | ||||||||
<6 Months | 47 (100.0) | Reference | Reference | |||||
6–12 Months | 132 (100.0) | 0.52 (-3.40–4.43) | 0.795 | 0.94 (-2.93–4.92) | 0.619 | |||
>12 Months | 395 (100.0) | 1.14 (-2.41–4.70) | 0.528 | 1.24 (-2.37–4.85) | 0.677 | |||
Presence of basic diseases* | ||||||||
No | 487 (66.9) | Reference | Reference | |||||
Yes | 154 (74.0) | 2.69 (0.50–4.88) | 0.016* | 3.47 (1.20–5.73) | 0.003* |